Latest & greatest articles for cannabis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cannabis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cannabis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cannabis

181. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Full Text available with Trip Pro

Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Rimonabant is a selective type 1 cannabinoid (CB1) receptor antagonist. It may assist with smoking cessation by restoring the balance of the endocannabinoid system, which can be disrupted by prolonged use of nicotine. Rimonabant also seeks to address many smokers' reluctance to persist with a quit attempt because of concerns about weight gain.To determine whether selective CB1 receptor antagonists increase the numbers

2007 Cochrane

182. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis: a Northern European perspective

Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis: a Northern European perspective Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

183. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain

Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

184. Cost-effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe

Cost-effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe Cost-effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe Cost-effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe Canonica G W, Poulsen P B, Vestenbaek U Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study objective was to assess the cost-effectiveness of an allergen specific immunotherapy (SIT), GRAZAX, for home treatment of grass pollen-induced rhinoconjunctivitis in Southern Europe. The authors concluded that allergen SIT with GRAZAX was a cost-effectiveness strategy in comparison with usual care, from

2007 NHS Economic Evaluation Database.

185. Cannabis use increases the risk of young people developing psychotic symptoms, particularly if already predisposed Full Text available with Trip Pro

Cannabis use increases the risk of young people developing psychotic symptoms, particularly if already predisposed Cannabis use increases the risk of young people developing psychotic symptoms, particularly if already predisposed | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Cannabis use increases the risk of young people developing psychotic symptoms, particularly if already predisposed Article Text Aetiology Cannabis use increases

2006 Evidence-Based Mental Health

186. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. Full Text available with Trip Pro

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. Rimonabant, a selective cannabinoid-1 receptor blocker, may reduce body weight and improve cardiometabolic risk factors in patients who are overweight or obese.To compare the efficacy and safety of rimonabant with placebo each in conjunction with diet and exercise for sustained changes in weight and cardiometabolic

2006 JAMA Controlled trial quality: predicted high

187. Efficacy of marijuana in treating chronic non cancer pain: a short review

in treating chronic non cancer pain: a short review. Richmond: WorkSafe BC. 2006 Authors' objectives The objectives of this short systematic review are to answer following questions: Is cannabis or cannabinoid, natural or synthetic (including Marinol, Sativex, Cesamet) effective in treating chronic non cancer pain? Is there any new evidence to change the WorkSafeBC policy on marijuana use in treating chronic non cancer pain? Authors' conclusions At present, there is no evidence on the effectiveness (...) of cannabis or cannabinoids in treating patients with chronic non-malignant pain. Given the current availability of evidence on the effectiveness of cannabis or cannabinoids on treating chronic non-malignant pain, the EBPG suggests that the WorkSafeBC policy on the 'medicinal use' of cannabis or cannabinoids in treating chronic pain, as outlined in the 2002 paper entitled "Marijuana for medicinal purposes: an evidence based assessment" remains appropriate and should not be modified. Project page URL

2006 Health Technology Assessment (HTA) Database.

188. Sublingual immunotherapy with a grass allergen tablet improved symptoms and quality of life in allergic rhinoconjunctivitis

Sublingual immunotherapy with a grass allergen tablet improved symptoms and quality of life in allergic rhinoconjunctivitis Sublingual immunotherapy with a grass allergen tablet improved symptoms and quality of life in allergic rhinoconjunctivitis | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Sublingual immunotherapy with a grass allergen tablet improved symptoms and quality of life in allergic rhinoconjunctivitis Article Text

2006 Evidence-Based Medicine

189. Cannabis intoxication and fatal road crashes in France: population based case-control study. Full Text available with Trip Pro

Cannabis intoxication and fatal road crashes in France: population based case-control study. To evaluate the relative risk of being responsible for a fatal crash while driving under the influence of cannabis, the prevalence of such drivers within the driving population, and the corresponding share of fatal crashes.Population based case-control study.10 748 drivers, with known drug and alcohol concentrations, who were involved in fatal crashes in France from October 2001 to September 2003 (...) .The cases were the 6766 drivers considered at fault in their crash; the controls were 3006 drivers selected from the 3982 other drivers. Positive detection of cannabis was defined as a blood concentration of Delta9tetrahydrocannabinol of over 1 ng/ml. The prevalence of positive drivers in the driving population was estimated by standardising controls on drivers not at fault who were involved in crashes resulting in slight injuries.681 drivers were positive for cannabis (cases 8.8%, controls 2.8

2005 BMJ

190. Review: current evidence does not show a strong causal relation between the use of cannabis in young people and psychosocial harm Full Text available with Trip Pro

Review: current evidence does not show a strong causal relation between the use of cannabis in young people and psychosocial harm Review: current evidence does not show a strong causal relation between the use of cannabis in young people and psychosocial harm | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: current evidence does not show a strong causal relation between the use of cannabis in young people and psychosocial harm

2005 Evidence-Based Mental Health

191. Project ALERT reduces initiation of cigarette and marijuana use in 12–14 year olds Full Text available with Trip Pro

Project ALERT reduces initiation of cigarette and marijuana use in 12–14 year olds Project ALERT reduces initiation of cigarette and marijuana use in 12–14 year olds | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Project ALERT reduces initiation of cigarette and marijuana use in 12–14 year olds Article Text Therapeutics Project ALERT reduces initiation of cigarette and marijuana use in 12–14 year olds Free Steve Sussman , PhD FAAHB

2005 Evidence-Based Mental Health

192. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Full Text available with Trip Pro

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. In animal models, cannabinoid-1 receptor (CB1) blockade produces a lean phenotype, with resistance to diet-induced obesity and associated dyslipidaemia. We assessed the effect of rimonabant, a selective CB1 blocker, on bodyweight and cardiovascular risk factors in overweight or obese patients.patients with body-mass

2005 Lancet Controlled trial quality: uncertain

193. Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy

Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy Petersen K D, Gyrd Hansen D, Dahl R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared treatment with specific immunotherapy (SIT) with symptomatic treatment or standard care amongst patients with grass pollen or mite allergy. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised 16- to 60-year-old patients who had started SIT during

2005 NHS Economic Evaluation Database.

194. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. Full Text available with Trip Pro

Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. To investigate the relation between cannabis use and psychotic symptoms in individuals with above average predisposition for psychosis who first used cannabis during adolescence.Analysis of prospective data from a population based sample. Assessment of substance use, predisposition for psychosis, and psychotic symptoms was based on standardised personal interviews at baseline (...) and at follow up four years later.2437 young people (aged 14 to 24 years) with and without predisposition for psychosis.Psychotic symptoms at follow up as a function of cannabis use and predisposition for psychosis at baseline.After adjustment for age, sex, socioeconomic status, urbanicity, childhood trauma, predisposition for psychosis at baseline, and use of other drugs, tobacco, and alcohol, cannabis use at baseline increased the cumulative incidence of psychotic symptoms at follow up four years later

2005 BMJ

195. Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002. Full Text available with Trip Pro

Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002. Among illicit substance use disorders, marijuana use disorders are the most prevalent in the population. Yet, information about the prevalence of current Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) marijuana use disorders and how prevalence has changed is lacking.To examine changes in the prevalence of marijuana use, abuse, and dependence in the United States between 1991-1992 (...) and 2001-2002.Face-to-face interviews were conducted in 2 large national surveys conducted 10 years apart: the 1991-1992 National Longitudinal Alcohol Epidemiologic Survey ([NLAES] n = 42,862) and the 2001-2002 National Epidemiologic Survey on Alcohol and Related Conditions ([NESARC] n = 43,093).Rates of past year marijuana use, abuse, and dependence.Among the adult US population, the prevalence of marijuana use remained stable at about 4.0% over the past decade. In contrast, the prevalence of DSM-IV

2004 JAMA

196. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. Full Text available with Trip Pro

Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. The empirical literature on treatment of obsessive-compulsive disorder (OCD) in children and adolescents supports the efficacy of short-term OCD-specific cognitive-behavior therapy (CBT) or medical management with selective serotonin reuptake inhibitors. However, little is known about their relative

2004 JAMA Controlled trial quality: predicted high

197. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Full Text available with Trip Pro

Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. To evaluate the effect of the oral synthetic delta-9-tetrahydrocannabinol dronabinol on central neuropathic pain in patients with multiple sclerosis.Randomised double blind placebo controlled crossover trial.Outpatient clinic, University Hospital of Aarhus, Denmark.24 patients aged between 23 and 55 years with multiple sclerosis and central pain.Orally

2004 BMJ Controlled trial quality: predicted high

198. The Cannabis Youth Treatment (CYT) study: main findings from two randomized trials

The Cannabis Youth Treatment (CYT) study: main findings from two randomized trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 NHS Economic Evaluation Database.

199. Food-aid cereals to reduce neurolathyrism related to grass-pea preparations during famine. (Abstract)

Food-aid cereals to reduce neurolathyrism related to grass-pea preparations during famine. Neurolathyrism is a spastic paraparesis that can be caused by excessive consumption of the drought-resistant grass pea (Lathyrus sativus). Devastating neurolathyrism epidemics have occurred during major famine crises in various parts of the world. We investigated in a case-control study the effects of food aid on risk of paralysis. Risk increased with consumption of boiled grass pea (adjusted odds ratio (...) 2.78, 95% CI 1.09-7.13 with cereals; 5.22, 2.01-13.55 without cereal) and raw unripe green grass pea (1.96, 1.16-3.31; p=0.011), but not with the fermented pancake, unleavened bread, and gravy preparations. In a correlational study there was an inverse relation between the number of new cases and the amount of food-aid cereals distributed per person. During famine, cereals and nutritional information should reach people before they have grass pea as the only food.

2003 Lancet

200. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. Full Text available with Trip Pro

Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. 1',1'dimethylheptyl-Delta8-tetrahydrocannabinol-11-oic acid (CT-3), a potent analog of THC-11-oic acid, produces marked antiallodynic and analgesic effects in animals without evoking the typical effects described in models of cannabinoids. Therefore, CT-3 may be an effective analgesic for poorly controlled resistant neuropathic pain.To examine the analgesic efficacy and safety of CT-3 (...) per day) or identical placebo capsules were given during the first 4 days and 8 capsules per day were given in 2 daily doses in the following 3 days. After a washout and baseline period of 1 week each, patients crossed over to the second 7-day treatment period.Visual analog scale (VAS) and verbal rating scale scores for pain; vital sign, hematologic and blood chemistry, and electrocardiogram measurements; scores on the Trail-Making Test and the Addiction Research Center Inventory-Marijuana scale

2003 JAMA Controlled trial quality: predicted high